10143886Establishment of an industrial base- and prime-editing platform for the identification of cancer drug resistance mechanisms and targets.ActiveCollaborative R&DInnovate UKCancer drug resistance is responsible for 80-90% of cancer-related deaths, making it a significant barrier to effective treatment (Mansoori,2017). Existing methods for characterising acquired resistance mechanisms are slow and reactive, identifying drug resistance only after it has occurred at scale in the clinic (Vasan et al.,2019). While CRISPR-Cas9 screening is effective for gene knockout studies, it lacks the precision to assess single-nucleotide changes, which are key drivers of cancer drug resistance. BaseRx is applying state of the art genome editing tools to prospectively identify single nucleotide variants driving resistance to cancer drugs thereby recapitulating the genetic diversity and tumour evolution observed across cancer patient populations in the laboratory and providing a platform for directly interpreting how variants affect response to therapy.